Active Studies
- TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer (ANETT) conducted at Houston Methodist, UT Health San Antonio, Utah
- Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer (Olive Oil) conducted at Houston Methodist, UT Health San Antonio, Thomas Jefferson, Emory, Miami, Vanderbilt
- Phase I/Ib trial of Olaparib in combination with Vorinostat in patients with relapsed/refractory and/or metastatic breast cancer
- A first-in-class breakthrough therapy, a novel antimetastatic agent
- Trial of Olaparib + the ATR inhibitor AZD6738 or Olaparib + the WEE -1 kinase inhibitor AZD1775
Upcoming Studies
- Multicenter Phase II Trial of Neoadjuvant Trastuzumab Deruxtecan (DS-8201) and Anastrozole in ER-Positive, HER2-Positive and ER-Positive, HER2-Low Breast Cancers (Daiichi Trial)
- Multicenter Randomized Phase II Trial of Fulvestrant Plus Abemaciclib Versus Fulvestrant Plus Placebo in ER-Positive, HER2-Negative Metastatic Breast Cancer after Failure of Abemaciclib in Combination with an Aromatase Inhibitor (Lily Trial)
- Multicenter Phase II Trial of Durvalumab with Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)
- Multicenter Phase I/Ib Trial of Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory and/or Metastatic Breast Cancer (Olaparib Trial)